Literature DB >> 139910

Further evidence of response by leukaemia patients in remission to antigen(s) related to acute myelogenous leukaemia.

P Cocks, R L Powles, B Chapuis, P Alexander.   

Abstract

Fifteen patients with acute myelogenous leukaemia were studied to determine if their remission blood leucocytes could be stimulated into taking up [3H] thymidine after in vitro culture with their own cryo-preserved irradiated AML leukaemia cells. In 6/15 patients it was possible to show autologous recognition and equal recognition of their stored leukaemia cells, even when they had previously been maintained in in vitro proliferative cultures in liquid suspension and undergoing myeloid maturation for one week. After in vitro proliferative culture, 4 populations of leukaemia cells produced material in the supernatant media between 3 and 7 days capable of inducing [3H] thymidine uptake in autologous (2 pts, 5 supernatants) and allogeneic (2 pts, 2 supernatants) AML remission lymphocytes, but not in normal donor lymphocytes. The relevance of these observations to tumour-associated AML antigen is discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 139910      PMCID: PMC2025280          DOI: 10.1038/bjc.1977.39

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  Human leukemia-associated antigens: detection on cells of established lymphoblastoid lines.

Authors:  T Mohanakumar; J L Pauly; J E Sokal; R S Metzgar
Journal:  J Immunol       Date:  1975-12       Impact factor: 5.422

2.  Production and specificity of a blastogenic factor in mixed leucocyte cultures from twin sisters.

Authors:  S Kasakura
Journal:  Nature       Date:  1970-08-01       Impact factor: 49.962

3.  Stimulation of lymphocytes by autologous leukaemic cells in acute leukaemia.

Authors:  W H Fridman; F M Kourilsky
Journal:  Nature       Date:  1969-10-18       Impact factor: 49.962

4.  Human leukemia cell antigens: serologic characterization with xenoantisera.

Authors:  T Mohanakumar; R S Metzgar; D S Miller
Journal:  J Natl Cancer Inst       Date:  1974-05       Impact factor: 13.506

5.  Detection of monocyte specific antigen on human acute leukaemia cells.

Authors:  M A Baker; R E Falk; J Falk; M F Greaves
Journal:  Br J Haematol       Date:  1976-01       Impact factor: 6.998

6.  Safe method of collecting leukaemia cells from patients with acute leukaemia for use as immunotherapy.

Authors:  R L Powles; T A Lister; R T Oliver; J Russell; C Smith; H E Kay; T J McElwain; G H Fairley
Journal:  Br Med J       Date:  1974-11-16

7.  Recognition of leukaemia cells as foreign before and after autoimmunization.

Authors:  R L Powles; L A Balchin; G H Fairley; P Alexander
Journal:  Br Med J       Date:  1971-02-27

8.  Spontaneous shedding of TSTA by viable sarcoma cells: its possible role in facilitating metastatic spread.

Authors:  G A Currie; P Alexander
Journal:  Br J Cancer       Date:  1974-01       Impact factor: 7.640

9.  Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient.

Authors:  R L Powles; J Russell; T A Lister; T Oliver; J M Whitehouse; J Malpas; B Chapuis; D Crowther; P Alexander
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640

10.  Immunotherapy for acute myelogenous leukaemia.

Authors:  R L Powles; D Crowther; C J Bateman; M E Beard; T J McElwain; J Russell; T A Lister; J M Whitehouse; P F Wrigley; M Pike; P Alexander; G H Fairley
Journal:  Br J Cancer       Date:  1973-11       Impact factor: 7.640

View more
  2 in total

1.  Immunotherapy in the treatment of acute myelogenous leukemia (AML): rationale, results and future prospects.

Authors:  D Urbanitz; T Büchner; H Pielken; J van de Loo
Journal:  Klin Wochenschr       Date:  1983-10-03

2.  Failure to detect autologous antibodies in the remission sera of patients with AML: complications introduced by the presence of rheumatoid factor.

Authors:  S E James; C J Dean; P Alexander
Journal:  Br J Cancer       Date:  1980-09       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.